JP2022065063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022065063A5 JP2022065063A5 JP2022019435A JP2022019435A JP2022065063A5 JP 2022065063 A5 JP2022065063 A5 JP 2022065063A5 JP 2022019435 A JP2022019435 A JP 2022019435A JP 2022019435 A JP2022019435 A JP 2022019435A JP 2022065063 A5 JP2022065063 A5 JP 2022065063A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- set forth
- region set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- 102000004388 Interleukin-4 Human genes 0.000 claims 4
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 229940028885 interleukin-4 Drugs 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000000592 Nasal Polyps Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000016366 nasal cavity polyp Diseases 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 1
- 101500027172 Homo sapiens Soluble interleukin-4 receptor subunit alpha Proteins 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610399254.4 | 2016-06-08 | ||
| CN201610399254.4A CN107474134B (zh) | 2016-06-08 | 2016-06-08 | 用于结合白细胞介素4受体的抗体 |
| JP2018564202A JP7025356B2 (ja) | 2016-06-08 | 2017-06-08 | インターロイキン‐４受容体への結合のための抗体 |
| PCT/CN2017/087592 WO2017211319A1 (zh) | 2016-06-08 | 2017-06-08 | 用于结合白细胞介素4受体的抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564202A Division JP7025356B2 (ja) | 2016-06-08 | 2017-06-08 | インターロイキン‐４受容体への結合のための抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022065063A JP2022065063A (ja) | 2022-04-26 |
| JP2022065063A5 true JP2022065063A5 (enExample) | 2022-06-13 |
Family
ID=60577597
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564202A Active JP7025356B2 (ja) | 2016-06-08 | 2017-06-08 | インターロイキン‐４受容体への結合のための抗体 |
| JP2022019435A Pending JP2022065063A (ja) | 2016-06-08 | 2022-02-10 | インターロイキン‐４受容体への結合のための抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564202A Active JP7025356B2 (ja) | 2016-06-08 | 2017-06-08 | インターロイキン‐４受容体への結合のための抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20190177408A1 (enExample) |
| EP (2) | EP4420671A3 (enExample) |
| JP (2) | JP7025356B2 (enExample) |
| KR (2) | KR102502988B1 (enExample) |
| CN (2) | CN107474134B (enExample) |
| AU (2) | AU2017276473B2 (enExample) |
| BR (1) | BR112018074325A2 (enExample) |
| CA (1) | CA3026568A1 (enExample) |
| ES (1) | ES3007134T3 (enExample) |
| IL (1) | IL263268B2 (enExample) |
| MX (1) | MX2018014941A (enExample) |
| MY (1) | MY189035A (enExample) |
| PH (1) | PH12018502544B1 (enExample) |
| SA (1) | SA518400605B1 (enExample) |
| SG (1) | SG11201810855VA (enExample) |
| UA (1) | UA124835C2 (enExample) |
| WO (1) | WO2017211319A1 (enExample) |
| ZA (1) | ZA201808209B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| KR102652133B1 (ko) * | 2018-02-01 | 2024-03-29 | 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 | IL-4Rα 항체 및 그 용도 |
| CN108373505B (zh) * | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
| EP3793597A1 (en) | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
| CN113101364B (zh) | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技（成都）有限公司 | 一种自免疫抑制剂的开发和应用 |
| CN110872349A (zh) | 2018-09-04 | 2020-03-10 | 三生国健药业（上海）股份有限公司 | 结合人il-4r的抗体、其制备方法和用途 |
| CN111494625B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| CN111686247B (zh) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
| CN112010977B (zh) * | 2019-05-29 | 2022-04-26 | 山东博安生物技术股份有限公司 | 抗白介素4受体(il-4r)的抗体及其应用 |
| WO2021195530A1 (en) | 2020-03-27 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CN113527485B (zh) | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
| KR20230015965A (ko) | 2020-05-22 | 2023-01-31 | 리제너론 파아마슈티컬스, 인크. | Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법 |
| CN111690066B (zh) * | 2020-06-22 | 2022-07-22 | 南京融捷康生物科技有限公司 | 抗IL-4Rα的单域抗体以及应用和药物 |
| EP4211169A4 (en) * | 2020-09-10 | 2024-12-04 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | ANTIBODIES THAT SPECIFICALLY RECOGNIZE THE INTERLEUKIN-4 RECEPTOR ALPHA AND USES THEREOF |
| US20220169739A1 (en) | 2020-10-05 | 2022-06-02 | Sanofi Biotechnology | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
| WO2022150605A1 (en) | 2021-01-08 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist |
| JP2024529434A (ja) | 2021-07-26 | 2024-08-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによる慢性自発性蕁麻疹を治療するための方法 |
| JP2024532263A (ja) | 2021-08-23 | 2024-09-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法 |
| AU2022369296A1 (en) | 2021-10-20 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating prurigo nodularis by administering an il-4r antagonist |
| AU2022425608A1 (en) | 2021-12-30 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
| AU2023228815A1 (en) | 2022-03-02 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
| CA3250514A1 (en) | 2022-05-02 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | ANTI-INTERLEUKIN-4 (IL-4R) RECEPTOR ANTIBODIES |
| EP4518839A2 (en) | 2022-05-02 | 2025-03-12 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity |
| MA71395A (fr) | 2022-07-08 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles chez un sujet pédiatrique par administration d'un antagoniste d'il-4 r |
| WO2024047021A1 (en) | 2022-08-29 | 2024-03-07 | Sanofi | Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist |
| WO2024097714A1 (en) | 2022-11-01 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
| WO2024112935A1 (en) | 2022-11-23 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for improving bone growth by administering an il-4r antagonist |
| TW202502819A (zh) | 2023-03-22 | 2025-01-16 | 法商賽諾菲生物技術公司 | 藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法 |
| TW202502820A (zh) | 2023-03-27 | 2025-01-16 | 美商再生元醫藥公司 | 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法 |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| US20250388685A1 (en) | 2024-04-15 | 2025-12-25 | Sanofi Biotechnology | Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist |
| US20260070995A1 (en) | 2024-09-09 | 2026-03-12 | Marcella Ruddy | Methods for treating bullous pemphigoid by administering an il-4r antagonist |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE16192152T1 (de) | 2000-05-26 | 2020-08-06 | Immunex Corporation | Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon |
| GEP20104991B (en) * | 2003-11-07 | 2010-05-25 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
| US20070212301A1 (en) * | 2003-11-07 | 2007-09-13 | Amgen, Inc. | Monkey Immunoglobulin Sequences |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008054606A2 (en) * | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US20110008326A1 (en) * | 2008-04-02 | 2011-01-13 | Oliver Hill | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| PL2624865T3 (pl) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R) |
| JP6013915B2 (ja) * | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| ES2863410T3 (es) * | 2011-12-13 | 2021-10-11 | Pieris Pharmaceuticals Gmbh | Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores. |
| WO2014031610A1 (en) | 2012-08-21 | 2014-02-27 | Sanofi | Methods for treating or preventing asthma by administering an il-4r antagonist |
| HRP20181227T1 (hr) | 2012-09-07 | 2018-10-05 | Regeneron Pharmaceuticals, Inc. | Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| EP3099323A4 (en) | 2014-01-27 | 2017-10-04 | Medlmmune, LLC | Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung |
| RU2704999C2 (ru) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Способ лечения кожной инфекции путем введения антагониста il-4r |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| CN109789196B (zh) | 2016-09-01 | 2024-03-19 | 瑞泽恩制药公司 | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 |
| CN108339118A (zh) | 2017-01-23 | 2018-07-31 | 瑞阳(苏州)生物科技有限公司 | 治疗或预防阻塞性睡眠呼吸暂停的药物组合物 |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| PL3703818T3 (pl) | 2017-10-30 | 2024-03-25 | Sanofi Biotechnology | Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie |
| EP3793597A1 (en) | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
| EP3878868B1 (en) | 2018-11-09 | 2024-10-09 | Ajou University Industry-Academic Cooperation Foundation | Human antibody having high affinity to human il-4 receptor alpha, and use thereof |
| SG11202109003QA (en) | 2019-03-06 | 2021-09-29 | Regeneron Pharma | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
| CN111686247B (zh) | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
-
2016
- 2016-06-08 CN CN201610399254.4A patent/CN107474134B/zh active Active
- 2016-06-08 CN CN202110760590.8A patent/CN113372446A/zh not_active Withdrawn
-
2017
- 2017-06-08 KR KR1020227022353A patent/KR102502988B1/ko active Active
- 2017-06-08 BR BR112018074325-9A patent/BR112018074325A2/pt unknown
- 2017-06-08 IL IL263268A patent/IL263268B2/en unknown
- 2017-06-08 MY MYPI2018002201A patent/MY189035A/en unknown
- 2017-06-08 CA CA3026568A patent/CA3026568A1/en active Pending
- 2017-06-08 JP JP2018564202A patent/JP7025356B2/ja active Active
- 2017-06-08 US US16/307,930 patent/US20190177408A1/en not_active Abandoned
- 2017-06-08 ES ES17809758T patent/ES3007134T3/es active Active
- 2017-06-08 EP EP24177229.2A patent/EP4420671A3/en active Pending
- 2017-06-08 MX MX2018014941A patent/MX2018014941A/es unknown
- 2017-06-08 SG SG11201810855VA patent/SG11201810855VA/en unknown
- 2017-06-08 PH PH1/2018/502544A patent/PH12018502544B1/en unknown
- 2017-06-08 KR KR1020197000454A patent/KR102417217B1/ko active Active
- 2017-06-08 EP EP17809758.0A patent/EP3470430B1/en active Active
- 2017-06-08 AU AU2017276473A patent/AU2017276473B2/en active Active
- 2017-06-08 UA UAA201900001A patent/UA124835C2/uk unknown
- 2017-06-08 WO PCT/CN2017/087592 patent/WO2017211319A1/zh not_active Ceased
-
2018
- 2018-12-05 ZA ZA2018/08209A patent/ZA201808209B/en unknown
- 2018-12-06 SA SA518400605A patent/SA518400605B1/ar unknown
-
2020
- 2020-03-04 US US16/809,411 patent/US10774141B2/en active Active
- 2020-08-14 US US16/994,464 patent/US11866491B2/en active Active
-
2022
- 2022-02-10 JP JP2022019435A patent/JP2022065063A/ja active Pending
-
2023
- 2023-11-15 US US18/510,553 patent/US20240190954A1/en active Pending
-
2024
- 2024-08-02 AU AU2024205464A patent/AU2024205464A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022065063A5 (enExample) | ||
| CN114729037B (zh) | 抗tslp抗体及其用途 | |
| RU2559525C2 (ru) | Белки, связывающие простагландин е2, и их применение | |
| ES2817756T3 (es) | Proteínas de unión a interleuquina-13 | |
| CN108350070B (zh) | 胸腺基质淋巴细胞生成素(tslp)-结合分子及该分子的使用方法 | |
| CN108367075B (zh) | 4-1bb结合蛋白及其用途 | |
| JP2020023523A5 (enExample) | ||
| JP2008527989A5 (enExample) | ||
| CN110105451B (zh) | IL-4Rα抗体及其用途 | |
| JP2011508592A5 (enExample) | ||
| CN107428828A (zh) | Tslp结合蛋白 | |
| JP2010500005A5 (enExample) | ||
| MX2014004980A (es) | Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17. | |
| KR20190107184A (ko) | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| JP2009523154A5 (enExample) | ||
| JP2009533020A5 (enExample) | ||
| JP2011527579A5 (enExample) | ||
| TW202140550A (zh) | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 | |
| CN114867748A (zh) | 结合胸腺基质淋巴细胞生成素(tslp)的抗体的干粉制剂及其使用方法 | |
| JPWO2021170020A5 (enExample) | ||
| JPWO2022040345A5 (enExample) | ||
| WO2022007965A1 (zh) | 一种抗IgE的工程化抗体及其应用 | |
| NZ749151B2 (en) | Antibody for binding to interleukin 4 receptor | |
| RU2019100002A (ru) | Антитело для связывания с рецептором интерлейкина 4 | |
| AU2014202979A1 (en) | Prostaglandin E2 binding proteins and uses thereof |